A 24-week Open-label Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

First-in-man Study of Single Ascending Dose of a New Drug for Neurological Disorders

NCT02719197 ·Status: COMPLETED ·Phase: PHASE1

Efficacy, Safety, and Pharmacokinetics/Pharmacodynamic Study of L-Dopa/Carbidopa To Treat Parkinson's Disease

NCT00558337 ·Status: COMPLETED ·Phase: PHASE2

A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations

NCT03703570 ·Status: COMPLETED ·Phase: PHASE2

Observational Study for Non-motor Symptoms and Treatment in Parkinson's Disease Patients

NCT02073981 ·Status: COMPLETED

Effects of Monoamine Reuptake Inhibitor NS2330 in Parkinson's Disease

NCT00006077 ·Status: COMPLETED ·Phase: PHASE2

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ODM-103 in Healthy Volunteers

NCT01688089 ·Status: COMPLETED ·Phase: PHASE1

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Safety, Tolerability and Efficacy of E2007 in Parkinson's Disease Patients With "Wearing Off" Motor Fluctuations and "On" Period Dyskinesias

NCT01172379 ·Status: COMPLETED ·Phase: PHASE2

Safety, Tolerability, and Pharmacokinetics of Oral FB-101 in Healthy Subjects

NCT04165837 ·Status: COMPLETED ·Phase: PHASE1

A Study of Single and Multiple Doses of KW-6356 in Healthy Subjects

NCT03830528 ·Status: COMPLETED ·Phase: PHASE1

A Study to Evaluate the Safety, Tolerability and Efficacy of MT101-5 in Subjects with Early Parkinson's Disease

NCT06175767 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

A Study to Evaluate the Efficacy of 18 to 24mg/Day Ropinirole Controlled Release (CR) Tablets in Early and Advanced Parkinson's Disease (PD) Patients.

NCT01929317 ·Status: TERMINATED ·Phase: PHASE3

A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in Healthy Subjects

NCT05238701 ·Status: COMPLETED ·Phase: PHASE1

Trial of Valproic Acid in Patients With Progressive Supranuclear Palsy (Depakine)

NCT00385710 ·Status: COMPLETED ·Phase: PHASE2

A Phase 3, Long-term, Extension Study of TVP-1012 (1 mg) in Early Parkinson's Disease Participants

NCT02337751 ·Status: COMPLETED ·Phase: PHASE3

Ambroxol as a Disease-modifying Treatment in GBA-PD

NCT05287503 ·Status: COMPLETED ·Phase: PHASE2

First-in-man Study of Single and Multiple Ascending Doses of a New Drug for Neurological Disorders

NCT02702648 ·Status: COMPLETED ·Phase: PHASE1

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease

NCT02373072 ·Status: COMPLETED ·Phase: PHASE1

A Safety and Pharmacokinetics Study of UCB7853 in Healthy Study Participants and Study Participants With Parkinson's Disease (PD)

NCT04651153 ·Status: COMPLETED ·Phase: PHASE1

A Pilot Trial of Lithium in Subjects With Progressive Supranuclear Palsy or Corticobasal Degeneration

NCT00703677 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Study to Assess the Safety of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive Impairment

NCT03713957 ·Status: COMPLETED ·Phase: PHASE2

Efficacy and Safety of MT-5199 in Subjects With Tardive Dyskinesia

NCT03176771 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Phase I Open-label Study of Low-dose Ketamine Infusion Treatment in Levodopa-Induced Dyskinesia in Parkinson's Disease

NCT06021756 ·Status: UNKNOWN ·Phase: PHASE1

2 Year Study to Evaluate the Effects of GPI 1485 on [123I]b-CIT/SPECTScanning and Clinical Efficacy in Patients With PD

NCT00209508 ·Status: COMPLETED ·Phase: PHASE2

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Parkinson's Disease

NCT06732180 ·Status: RECRUITING ·Phase: PHASE1

A Single Oral Dose, Crossover Comparative PK Study of WD-1603 in Healthy Subjects Under Fasting Conditions

NCT04553978 ·Status: UNKNOWN ·Phase: PHASE1